PARP1 and cancer: The sensitivity of the phenocopy signatures in mutation-negative cancer cell lines was on par with DNA alterations for EGFR, BRAF, and MAPK, and better than DNA alterations for PI3K-AKT, PARP/HRD, ERBB2, MTOR, and JAK.